001     127757
005     20240228135033.0
024 7 _ |a 10.1093/hmg/ddt599
|2 doi
024 7 _ |a pmid:24282031
|2 pmid
024 7 _ |a 0964-6906
|2 ISSN
024 7 _ |a 1460-2083
|2 ISSN
037 _ _ |a DKFZ-2017-03779
041 _ _ |a eng
082 _ _ |a 570
100 1 _ |a Kuhmann, Christine
|0 P:(DE-HGF)0
|b 0
|e First author
245 _ _ |a Altered regulation of DNA ligase IV activity by aberrant promoter DNA methylation and gene amplification in colorectal cancer.
260 _ _ |a Oxford
|c 2014
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1506604045_7124
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Colorectal cancer (CRC) presents as a very heterogeneous disease which cannot sufficiently be characterized with the currently known genetic and epigenetic markers. To identify new markers for CRC we scrutinized the methylation status of 231 DNA repair-related genes by methyl-CpG immunoprecipitation followed by global methylation profiling on a CpG island microarray, as altered expression of these genes could drive genomic and chromosomal instability observed in these tumors. We show for the first time hypermethylation of MMP9, DNMT3A and LIG4 in CRC which was confirmed in two CRC patient groups with different ethnicity. DNA ligase IV (LIG4) showed strong differential promoter methylation (up to 60%) which coincided with downregulation of mRNA in 51% of cases. This functional association of LIG4 methylation and gene expression was supported by LIG4 re-expression in 5-aza-2'-deoxycytidine-treated colon cancer cell lines, and reduced ligase IV amounts and end-joining activity in extracts of tumors with hypermethylation. Methylation of LIG4 was not associated with other genetic and epigenetic markers of CRC in our study. As LIG4 is located on chromosome 13 which is frequently amplified in CRC, two loci were tested for gene amplification in a subset of 47 cases. Comparison of amplification, methylation and expression data revealed that, in 30% of samples, the LIG4 gene was amplified and methylated, but expression was not changed. In conclusion, hypermethylation of the LIG4 promoter is a new mechanism to control ligase IV expression. It may represent a new epigenetic marker for CRC independent of known markers.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Biomarkers, Tumor
|2 NLM Chemicals
650 _ 7 |a LIG4 protein, human
|2 NLM Chemicals
650 _ 7 |a RNA, Messenger
|2 NLM Chemicals
650 _ 7 |a DNA (Cytosine-5-)-Methyltransferase
|0 EC 2.1.1.37
|2 NLM Chemicals
650 _ 7 |a DNA methyltransferase 3A
|0 EC 2.1.1.37
|2 NLM Chemicals
650 _ 7 |a MMP9 protein, human
|0 EC 3.4.24.35
|2 NLM Chemicals
650 _ 7 |a Matrix Metalloproteinase 9
|0 EC 3.4.24.35
|2 NLM Chemicals
650 _ 7 |a DNA Ligases
|0 EC 6.5.1.-
|2 NLM Chemicals
650 _ 7 |a DNA Ligase ATP
|0 EC 6.5.1.1
|2 NLM Chemicals
700 1 _ |a Li, Carmen
|b 1
700 1 _ |a Kloor, Matthias
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Salou, Mariam
|0 P:(DE-He78)131e5921fcfccbf0f978d4426f1a615b
|b 3
|u dkfz
700 1 _ |a Weigel, Christoph
|0 P:(DE-He78)c566ec22a882273029b7cbe4ef700428
|b 4
|u dkfz
700 1 _ |a Schmidt, Christopher R
|b 5
700 1 _ |a Ng, Linda W C
|b 6
700 1 _ |a Tsui, Wendy W Y
|b 7
700 1 _ |a Leung, Suet Y
|b 8
700 1 _ |a Yuen, Siu T
|b 9
700 1 _ |a Becker, Natalia
|0 P:(DE-He78)ecb33fb615e08035fdcefcaebfdff8f0
|b 10
|u dkfz
700 1 _ |a Weichenhan, Dieter
|0 P:(DE-He78)ff4024f7bc236e7897d9c18ee19c451f
|b 11
|u dkfz
700 1 _ |a Plass, Christoph
|0 P:(DE-He78)4301875630bc997edf491c694ae1f8a9
|b 12
|u dkfz
700 1 _ |a Schmezer, Peter
|0 P:(DE-He78)141ce740f5d881812d2675147b72ecaf
|b 13
|u dkfz
700 1 _ |a Chan, Tsun L
|b 14
700 1 _ |a Popanda, Odilia
|0 P:(DE-He78)37610ef78c733753f0836ce0e41b9fda
|b 15
|e Last author
|u dkfz
773 _ _ |a 10.1093/hmg/ddt599
|g Vol. 23, no. 8, p. 2043 - 2054
|0 PERI:(DE-600)1474816-2
|n 8
|p 2043 - 2054
|t Human molecular genetics
|v 23
|y 2014
|x 1460-2083
909 C O |o oai:inrepo02.dkfz.de:127757
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)131e5921fcfccbf0f978d4426f1a615b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)c566ec22a882273029b7cbe4ef700428
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)ecb33fb615e08035fdcefcaebfdff8f0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)ff4024f7bc236e7897d9c18ee19c451f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)4301875630bc997edf491c694ae1f8a9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)141ce740f5d881812d2675147b72ecaf
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)37610ef78c733753f0836ce0e41b9fda
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2014
915 _ _ |a Allianz-Lizenz / DFG
|0 StatID:(DE-HGF)0400
|2 StatID
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b HUM MOL GENET : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b HUM MOL GENET : 2015
920 1 _ |0 I:(DE-He78)C010-20160331
|k C010
|l Epigenomik und Krebsrisikofaktoren
|x 0
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 1
920 1 _ |0 I:(DE-He78)G105-20160331
|k G105
|l Gentherapie von Tumoren
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C010-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)G105-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21